TiGenix NV (LSE:0EIT) - Share price - Overview

Stock Report

TiGenix NV 0EIT

Last Price
-

Day Change
-|-%

As of -
- | EUR
Minimum 15 Minutes Delay.

Last Close-
Day Range-
Mkt Cap115.40Mil
52-Wk Range-
Yield %-
ISINBE0003864817
Volume-
P/E-
P/S-
P/CF-

Share Price

Financials
201220132014
More ...
Income Statement
Revenue4.084.300.34
Operating Income-18.28-16.01-12.56
Net Income-20.39-18.39-12.99
Basic EPS-0.22-0.16-0.08
Avg. Diluted Shares Outstanding92115160
Balance Sheet
Current Assets15.6424.1817.11
Non Current Assets48.3138.8636.81
Total Assets63.9663.0453.92
Current Liabilities9.085.888.48
Total Liabilities15.3914.8219.16
Total Equity48.5748.2234.76
Cash Flow
Operating Cash Flow-17.67-14.47-13.37
Capital Expenditure-0.72-0.36-0.36
Free Cash Flow-18.40-14.83-13.72

In millions, except "Basic EPS". Currency is EUR.

Company Profile

TiGenix NV is engaged in developing and commercializing novel therapeutics from its r proprietary technology platforms of allogeneic, or donor derived, stem cells.

Sector

Healthcare

Industry

Biotechnology

Stock Style

Small-Growth

Fiscal Year Ends

December

Employees

49
Key Stats
More ...
Price/Earning TTM-
Price/Book-
Price/Sales TTM-
Rev Growth (3 year avg)-33.44
EPS Growth (3 year avg)-
Operating Margin % TTM-3,716.86
Net Margin % TTM-3,843.20
ROE TTM-31.31
Debt/Equity0.31
Dividends
PreviousLatest
More ...
Declared Datet.b.c.t.b.c.
Ex-Divt.b.c.t.b.c.
Paidt.b.c.t.b.c.
Amnt0.000.00
AJ Bell includes AJ Bell Holdings Limited and its wholly owned subsidiaries. AJ Bell Management Limited and AJ Bell Securities Limited are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at Trafford House, Chester Road, Manchester M32 0RS. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2017 Morningstar. All rights reserved.